Future investigations could therefore focus on developing novel therapeutic strategies, such as inhibitors against the ZFHX4-SOX2 interaction or exploring whether targeting the downstream JAK-STAT pathway is an effective approach in gliomas characterized by high ZFHX4-AS1 expression. The gene discussed is SOAT1; the disease is central nervous system cancer.